Siemens syngo.PET Amyloid Plaque software cleared by FDA

The FDA has cleared Siemens Healthcare’s syngo.PET Amyloid Plaque proprietary software and it is now available for use with PET and PET/CT systems.

Designed to assist physicians with assessment of beta amyloid uptake ratios in PET scans of patients being evaluated for Alzheimer’s disease, the software registers PET amyloid images against a reference model of a PET amyloid brain to target regions of interest. Quantification of amyloid-PET images with standardized uptake value ratios could provide information in patients with possible mild cognitive impairment that is useful in supporting visual reads of amyloid-PET images, according to Siemens.

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.